IL216466B - Compositions for respiratory delivery of active agents and associated methods and systems - Google Patents

Compositions for respiratory delivery of active agents and associated methods and systems

Info

Publication number
IL216466B
IL216466B IL216466A IL21646611A IL216466B IL 216466 B IL216466 B IL 216466B IL 216466 A IL216466 A IL 216466A IL 21646611 A IL21646611 A IL 21646611A IL 216466 B IL216466 B IL 216466B
Authority
IL
Israel
Prior art keywords
preparations
systems
active agents
related methods
respiratory system
Prior art date
Application number
IL216466A
Other languages
English (en)
Hebrew (he)
Other versions
IL216466A0 (en
Original Assignee
Pearl Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42269864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL216466(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pearl Therapeutics Inc filed Critical Pearl Therapeutics Inc
Publication of IL216466A0 publication Critical patent/IL216466A0/en
Publication of IL216466B publication Critical patent/IL216466B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1025—Respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
IL216466A 2009-05-29 2011-11-20 Compositions for respiratory delivery of active agents and associated methods and systems IL216466B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US18256509P 2009-05-29 2009-05-29
US25817209P 2009-11-04 2009-11-04
US30936510P 2010-03-01 2010-03-01
US34553610P 2010-05-17 2010-05-17
PCT/US2010/036650 WO2010138862A2 (en) 2009-05-29 2010-05-28 Compositions for respiratory delivery of active agents and associated methods and systems

Publications (2)

Publication Number Publication Date
IL216466A0 IL216466A0 (en) 2012-01-31
IL216466B true IL216466B (en) 2018-08-30

Family

ID=42269864

Family Applications (3)

Application Number Title Priority Date Filing Date
IL216466A IL216466B (en) 2009-05-29 2011-11-20 Compositions for respiratory delivery of active agents and associated methods and systems
IL216468A IL216468B (en) 2009-05-29 2011-11-20 Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases
IL216467A IL216467B (en) 2009-05-29 2011-11-20 Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate or formoterol and their use in treatment of pulmonary diseases

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL216468A IL216468B (en) 2009-05-29 2011-11-20 Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate and formoterol and their use in treatment of pulmonary diseases
IL216467A IL216467B (en) 2009-05-29 2011-11-20 Pharmaceutical compositions deliverable from a metered dose inhaler comprising glycopyrrolate or formoterol and their use in treatment of pulmonary diseases

Country Status (31)

Country Link
US (12) US8808713B2 (enExample)
EP (6) EP2435024B1 (enExample)
JP (10) JP5873013B2 (enExample)
KR (7) KR101976107B1 (enExample)
CN (6) CN102596176B (enExample)
AR (3) AR076806A1 (enExample)
AU (3) AU2010253950C1 (enExample)
BR (3) BRPI1011220B1 (enExample)
CA (3) CA2763936C (enExample)
CY (8) CY1118040T1 (enExample)
DK (6) DK3106149T3 (enExample)
ES (6) ES2774367T3 (enExample)
FR (1) FR19C1040I2 (enExample)
HR (6) HRP20161102T1 (enExample)
HU (8) HUE047803T2 (enExample)
IL (3) IL216466B (enExample)
LT (8) LT2435024T (enExample)
LU (2) LUC00124I2 (enExample)
ME (1) ME03631B (enExample)
MX (5) MX337126B (enExample)
NL (1) NL300995I2 (enExample)
NO (2) NO2019026I1 (enExample)
PH (1) PH12017500778A1 (enExample)
PL (6) PL3106149T3 (enExample)
PT (6) PT2435024T (enExample)
RU (5) RU2016117972A (enExample)
SI (6) SI2435025T1 (enExample)
SM (6) SMT202000077T1 (enExample)
TW (9) TWI632926B (enExample)
WO (3) WO2010138868A2 (enExample)
ZA (4) ZA201108275B (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1494732T1 (sl) 2002-03-20 2008-08-31 Mannking Corp Inhalacijski aparat
JP5078014B2 (ja) 2004-08-20 2012-11-21 マンカインド コーポレイション ジケトピペラジン合成の触媒反応
JP4990142B2 (ja) 2004-08-23 2012-08-01 マンカインド コーポレイション 薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
US10002325B2 (en) 2005-03-30 2018-06-19 Primal Fusion Inc. Knowledge representation systems and methods incorporating inference rules
EP1937219B1 (en) 2005-09-14 2015-11-11 MannKind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
US9358352B2 (en) * 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN109568740B (zh) 2008-06-13 2022-05-27 曼金德公司 干粉吸入器和用于药物输送的系统
MX336361B (es) 2008-06-20 2015-12-03 Mannkind Corp Un metodo y un aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
SMT202000077T1 (it) * 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
US10474647B2 (en) 2010-06-22 2019-11-12 Primal Fusion Inc. Methods and devices for customizing knowledge representation systems
SG10201606220QA (en) 2011-04-01 2016-09-29 Mannkind Corp Blister package for pharmaceutical cartridges
EA201490991A1 (ru) * 2011-05-17 2014-09-30 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
CN105106200A (zh) * 2011-05-17 2015-12-02 珍珠治疗公司 用于呼吸递送两种或多种活性剂的组合物、方法和系统
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
GB201113662D0 (en) * 2011-08-08 2011-09-21 Prosonix Ltd Pharmaceutical compositions
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
BR112014025518B1 (pt) * 2012-04-13 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas
SG10201605800UA (en) 2012-07-12 2016-09-29 Mannkind Corp Dry powder drug delivery system and methods
CN102872027B (zh) * 2012-09-18 2014-03-12 刘晓忠 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备
WO2014115127A1 (en) * 2013-01-28 2014-07-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
CA2898682A1 (en) 2013-01-31 2014-08-07 Prosonix Limited Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy
GB201301721D0 (en) * 2013-01-31 2013-03-20 Prosonix Ltd Pharmaceutical Preparations
SI2964199T1 (sl) * 2013-03-04 2020-10-30 Besins Healthcare Luxembourg Sarl Suhi farmacevtski sestavki, ki obsegajo nanodelce aktivnega sredstva vezane na nosilne delce
US20150374623A1 (en) * 2013-03-14 2015-12-31 Novartis Ag Deamorphization of spray-dried formulations via spray-blending
MX361286B (es) * 2013-03-15 2018-12-03 Pearl Therapeutics Inc Métodos y sistemas para el acondicionamiento de materiales cristalinos de partículas.
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
CA2907566C (en) 2013-04-01 2023-08-22 Pulmatrix, Inc. Tiotropium dry powders
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
KR20160013134A (ko) * 2013-05-22 2016-02-03 펄 테라퓨틱스 인코포레이티드 3 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 및 시스템
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
PL3054920T3 (pl) * 2013-10-07 2021-07-05 Teva Branded Pharmaceutical Products R&D, Inc. Inhalator suchego proszku
TR201802607T4 (tr) * 2013-11-22 2018-03-21 Teva Branded Pharmaceutical Prod R & D Inc Bir solunabilir ilaç.
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
CN104188941B (zh) * 2014-09-02 2016-11-16 重庆和平制药有限公司 一种制备盐酸克仑特罗吸入粉雾剂的方法
US20180228818A1 (en) * 2014-10-01 2018-08-16 Chien-Hung Chen Pharmaceutical composition comprising asprin, metformin, and serotonin with non-ionic surfactant
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
TW201735914A (zh) 2015-12-22 2017-10-16 阿斯特捷利康公司 用於治療慢性阻塞性肺疾病之醫藥組成物
WO2017157265A1 (zh) * 2016-03-15 2017-09-21 广东东阳光药业有限公司 喷雾剂、喷雾装置以及喷雾组件
US20190269703A1 (en) * 2016-05-17 2019-09-05 Mayo Foundation For Medical Education And Research Materials and methods for treating chronic cough
ES3005760T3 (en) 2016-06-30 2025-03-17 Philip Morris Products Sa Nicotine particles
MX392213B (es) 2016-09-19 2025-03-21 Mexichem Fluor Sa De Cv Composiciones farmacéuticas que comprenden sales de glicopirrolato y 1,1-difluoroetano.
JP6906947B2 (ja) * 2016-12-22 2021-07-21 キヤノン株式会社 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム
CN106943350A (zh) * 2017-03-14 2017-07-14 上海现代药物制剂工程研究中心有限公司 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法
CN107243080B (zh) * 2017-06-21 2021-11-12 上海上药信谊药厂有限公司 一种吸入式气雾剂、其原料组合物及制备方法
IL302619B2 (en) * 2017-10-09 2024-06-01 Pearl Therapeutics Inc Drug delivery systems and related methods
JP7372727B2 (ja) 2017-11-20 2023-11-01 三菱重工業株式会社 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム
WO2020070620A2 (en) * 2018-10-01 2020-04-09 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
US20210386665A1 (en) * 2018-10-02 2021-12-16 Meijo University Educational Foundation Inhalation powder medicine, evaluation method thereof, and use thereof
CN109632555B (zh) * 2018-12-28 2021-07-27 上海新黄河制药有限公司 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法
WO2020229966A1 (en) * 2019-05-10 2020-11-19 Glenmark Pharmaceutical Limited Stable aerosol composition for inhalation comprising glycopyrronium
CN112137957B (zh) 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
US20200405700A1 (en) * 2019-06-27 2020-12-31 Cai Gu Huang Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide
CN112972384B (zh) * 2019-12-02 2022-03-18 长风药业股份有限公司 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法
CN120037526A (zh) * 2020-02-20 2025-05-27 奇斯药制品公司 包含缓冲药物制剂的加压定量吸入器
WO2021234366A1 (en) * 2020-05-18 2021-11-25 Orexo Ab New pharmaceutical composition for drug delivery
US20220000767A1 (en) * 2020-07-06 2022-01-06 Sensory Cloud, Inc. Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi
WO2022016068A1 (en) * 2020-07-16 2022-01-20 Tbd Pharma Llc Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections
TW202228690A (zh) 2020-09-29 2022-08-01 美商艾法瑪實驗室公司 茚達特羅(indacaterol)之液體調配物
TW202241410A (zh) * 2021-01-08 2022-11-01 大陸商江蘇恒瑞醫藥股份有限公司 可經由定量吸入器遞送的藥物組合物
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤
TW202317080A (zh) 2021-07-09 2023-05-01 美商阿斯特捷利康有限責任公司 用於氣溶膠遞送之組合物、方法及系統
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
WO2023119093A1 (en) 2021-12-20 2023-06-29 Astrazeneca Ab Compositions, methods and systems for aerosol drug delivery
CN116785239A (zh) * 2022-03-17 2023-09-22 上海惠永药物研究有限公司 喷雾冷冻干燥制备微球的方法
WO2023212191A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Combination of albuterol and budesonide for the treatment of asthma
WO2024206662A1 (en) * 2023-03-30 2024-10-03 Aerorx Therapeutics Llc Liquid formulations of indacaterol and glycopyrronium
CN117357485B (zh) * 2023-11-01 2024-09-24 山东京卫制药有限公司 一种改良的可吸入的载体颗粒及应用
US20250268914A1 (en) * 2024-02-26 2025-08-28 Honeywell International Inc. Fluticasone delivery compositions, devices and methods
CN118787617A (zh) * 2024-09-14 2024-10-18 苏州易合医药有限公司 一种吸入粉剂及其制备方法

Family Cites Families (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
SE378109B (enExample) 1972-05-19 1975-08-18 Bofors Ab
US4187301A (en) 1978-04-05 1980-02-05 Syntex (U.S.A.) Inc. 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes
ZA81976B (en) * 1980-02-15 1982-07-28 Glaxo Group Ltd Androstane carbothioates
ATE8790T1 (de) * 1981-02-02 1984-08-15 Schering Corporation Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten.
ZW6584A1 (en) 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
GB8432063D0 (en) 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
IL95590A (en) 1989-09-08 1996-06-18 Glaxo Group Ltd Medicinal preparations containing Salmetrol and Pluticasone Propionate
NZ235222A (en) 1989-09-08 1992-11-25 Glaxo Group Ltd Inhalatory composition comprising salmeterol and beclomethasone dipropionate
DE3931041C2 (de) 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
SG45171A1 (en) 1990-03-21 1998-01-16 Boehringer Ingelheim Int Atomising devices and methods
IE912999A1 (en) 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
PL165803B1 (pl) 1990-09-10 1995-02-28 Schering Corp Sposób wytwarzania nowego monohydratu 9a, 21-dichloro-16-a metylo-1,4-pregnadieno-11 ß , 17a-diolo-3,20-diono-17-(2’furanokarboksylanu) PL PL PL PL
DE4108393A1 (de) * 1991-03-15 1992-09-17 Boehringer Ingelheim Kg Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln
US5635563A (en) 1991-04-01 1997-06-03 Tomoegawa Paper Co., Ltd. Polyaniline derivatives and their production process
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
SK285910B6 (sk) 1991-12-18 2007-10-04 Aktiebolaget Astra Medicinálny produkt obsahujúci kombináciu formoterolu a budesonidu
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5849263A (en) 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
GB9313642D0 (en) * 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
EP0731688B1 (en) 1993-12-02 2003-03-05 Abbott Laboratories Aerosol drug formulations for use with non-cfc propellants
SE9404080L (sv) 1993-12-28 1995-06-29 Ciba Geigy Ag Förfarande för framställning av en optiskt ren enantiomer av formoterol
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
WO1995022036A1 (en) * 1994-02-09 1995-08-17 Kinerton Limited Process for drying a material from solution
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ATE236617T1 (de) * 1994-12-22 2003-04-15 Astrazeneca Ab Aerosol-arzneiformulierungen
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
CA2218074C (en) * 1995-04-14 2002-10-08 Mohammed Eljamal Powdered pharmaceutical formulations having improved dispersibility
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
US5833891A (en) * 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
DE19614421C2 (de) 1996-04-12 1999-12-16 Biovision Gmbh Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff
GB9610821D0 (en) 1996-05-23 1996-07-31 Glaxo Wellcome Inc Metering apparatus
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5886200A (en) * 1996-07-01 1999-03-23 Schering Corporation Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
SE9603669D0 (sv) 1996-10-08 1996-10-08 Astra Ab New combination
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
DK0937041T3 (da) * 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
PT1393721E (pt) 1997-03-20 2009-02-02 Schering Corp Forma de dosagem de aglomerados de pó
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US6010935A (en) 1997-08-21 2000-01-04 Micron Technology, Inc. Self aligned contacts
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
JP4526702B2 (ja) * 1997-09-29 2010-08-18 ネクター セラピューティックス 安定化生物活性処方物およびその使用方法
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) * 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US20020017295A1 (en) 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ID27083A (id) 1998-03-05 2001-02-22 Senju Pharma Co Komposisi farmasi untuk pencegahan dan pengobatan penyakit-penyakit yang behubungan dengan sitopati jaringan okuler fundus
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6260549B1 (en) * 1998-06-18 2001-07-17 Clavius Devices, Inc. Breath-activated metered-dose inhaler
US6451285B2 (en) * 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
CA2338753C (en) 1998-07-24 2006-11-21 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GB9912639D0 (en) * 1999-05-28 1999-07-28 Britannia Pharmaceuticals Ltd Improvements in and relating to treatment of respiratory conditions
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
NZ512383A (en) 1998-12-22 2003-05-30 Univ North Carolina Use of osmotic agents in the treatment of airway diseases and for the delivery of airway drugs
GB9902689D0 (en) * 1999-02-08 1999-03-31 Novartis Ag Organic compounds
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
SE9900833D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE60001492T2 (de) 1999-04-14 2003-12-18 Glaxo Group Ltd., Greenford Pharmazeutische aerosolformulierung
US20100197719A1 (en) * 1999-05-12 2010-08-05 Boehringer Ingelheim Pharma Kg Medicament compositions containing anticholinergically-effective compounds and betamimetics
DE60036214T2 (de) 1999-06-30 2008-05-21 Nektar Therapeutics, San Carlos Verfahren und system zur herstellung von trockenem pulver mittels sprühtrocknung
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
PT102343B (pt) * 1999-08-02 2003-11-28 Hovione Farmaciencia Sa Processo para a preparacao de furoato mometasona
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
EP1223915B1 (en) 1999-10-29 2005-12-21 Nektar Therapeutics Dry powder compositions having improved dispersivity
DE19961300A1 (de) * 1999-12-18 2001-06-21 Asta Medica Ag Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
IT1317846B1 (it) * 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PL358375A1 (en) 2000-04-13 2004-08-09 Innovata Biomed Limited Medicaments for treating respiratory disorders comprising formoterol and fluticasone
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
WO2002014293A1 (en) 2000-08-15 2002-02-21 Carsten Berg Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
US20040081627A1 (en) * 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6908928B2 (en) * 2000-10-12 2005-06-21 Bi Pharma Kg. Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions
NZ526059A (en) * 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
ATE382335T1 (de) * 2000-11-30 2008-01-15 Vectura Ltd Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation
GB0029562D0 (en) 2000-12-04 2001-01-17 Novartis Ag Organic compounds
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
EP1345629A2 (en) 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
IL157580A0 (en) * 2001-03-20 2004-03-28 Glaxo Group Ltd Inhalation drug combination
WO2002078761A1 (fr) * 2001-03-30 2002-10-10 Laboratoires Genevrier Neo-tissu cartilagineux greffable
DE50211045D1 (de) * 2001-03-30 2007-11-22 Jagotec Ag Medizinische aerosolformulierungen
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
DE10130371A1 (de) 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
TWI324934B (en) * 2001-08-28 2010-05-21 Schering Corp Pharmaceutical compositions for the treatment of asthma
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
DE10214264A1 (de) * 2002-03-28 2003-10-16 Boehringer Ingelheim Pharma HFA-Suspensionsformulierungen eines Anhydrats
US7244415B2 (en) 2002-03-28 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations of an anhydrate
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
DE10216429A1 (de) 2002-04-12 2003-10-23 Boehringer Ingelheim Pharma Arzneimittel enthaltend Steroide und ein neues Anticholinergikum
CN101700247A (zh) * 2002-06-12 2010-05-05 埃匹吉尼斯医药有限公司 利用脱氢表雄酮甾体及抗毒蕈碱药物治疗呼吸道疾病及肺病的组合物、制剂和试剂盒
US7244742B2 (en) * 2002-08-17 2007-07-17 Boehringer Ingelheim Pharma Gmbh & Co Kg Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic
DE10237739A1 (de) 2002-08-17 2004-02-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika
EP1542753B1 (en) 2002-08-23 2007-02-07 Schering Corporation Pharmaceutical compositions
AU2003279070A1 (en) 2002-09-30 2004-04-23 Acusphere Inc Sustained release porous microparticles for inhalation
AU2003279976B2 (en) * 2002-10-15 2007-10-11 Cryovac, Llc A process for triggering, storing, and distributing an oxygen scavenger, and a stored oxygen scavenger
EP1452179A1 (en) 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
DE10323966A1 (de) 2003-05-27 2004-12-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
KR20060015316A (ko) 2003-05-28 2006-02-16 넥타르 테라퓨틱스 아미노산 및/또는 인지질로 부분 또는 완전 코팅된수불용성 활성제 미립자의 제조를 위한 알코올성 수용액의분무 건조법
ES2383206T3 (es) 2003-06-16 2012-06-19 Nycomed Gmbh Composición que comprende un tensioactivo pulmonar y sildenafilo para el tratamiento de neumopatías
SE527190C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
JP2007500146A (ja) 2003-07-28 2007-01-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベータ受容体刺激薬及び抗コリン作用薬を含有する吸入用医薬品
AU2004262901B2 (en) 2003-07-29 2010-05-13 Boehringer Ingelheim International Gmbh Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation
EP1651270B1 (en) 2003-07-29 2007-03-21 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising betamimetics and an anticholinergic
EP1651224B1 (en) 2003-07-31 2011-10-05 Boehringer Ingelheim International GmbH Medicaments for inhalation comprising an anticholinergic and a betamimetic
EP1925293A3 (en) 2003-10-20 2010-01-13 Schering Corporation Pharmaceutical aerosol compositions
US9308199B2 (en) 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
WO2005051946A2 (en) * 2003-11-21 2005-06-09 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
AU2004312095A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
RU2438660C2 (ru) * 2004-02-06 2012-01-10 Меда Фарма Гмбх Унд Ко. Кг Комбинация и фармацевтический препарат для лечения воспалительных и обструктивных заболеваний дыхательных путей
WO2005074918A1 (en) 2004-02-06 2005-08-18 Benzstrasse 1 D-61352 Bad Homburd The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
US20050287077A1 (en) 2004-02-10 2005-12-29 James E. Shipley Process for preparing stable SOL of pharmaceutical ingredients and hydrofluorocarbon
GB0411056D0 (en) * 2004-05-18 2004-06-23 Novartis Ag Organic compounds
CN101014320B (zh) * 2004-06-18 2011-05-18 诺华疫苗和诊断公司 治疗支气管感染的组合物
GB0426301D0 (en) 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
US20060140873A1 (en) 2004-12-27 2006-06-29 Chang Heng W Aerosol pharmaceutical compositions
WO2006100453A1 (en) 2005-03-24 2006-09-28 Sosei R & D Ltd. Glycopyrronium salts and their therapeutic use
EP2484382A1 (en) 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
JP2008538758A (ja) 2005-04-23 2008-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗コリン作用薬に加えてベータ受容体刺激薬及びステロイドを含有する吸入用の医薬組成物
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
WO2006128847A2 (en) 2005-05-31 2006-12-07 Boehringer Ingelheim International Gmbh Medicament containing a betamimetic in conjunction with an anticholinergic and a pde iv inhibitor
JP2008543806A (ja) 2005-06-17 2008-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器疾患の治療のためのｍｒｐｉｖインヒビター
EP1906919A4 (en) 2005-07-15 2012-12-26 Map Pharmaceuticals Inc MULTIPLE ACTIVE PHARMACEUTICAL PRINCIPLES COMBINED IN DISCRETE INHALATION PARTICLES AND THEIR FORMULATIONS
WO2007009164A1 (en) 2005-07-15 2007-01-25 Eiffel Technologies Limited Method of particle formation
CN100560598C (zh) 2005-07-26 2009-11-18 上海奥锐特国际贸易有限公司 氟替卡松丙酸酯的合成方法
AT502396B1 (de) 2005-09-01 2007-03-15 Montanuniv Leoben Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
DE602006008665D1 (de) * 2005-12-21 2009-10-01 Meda Pharma Gmbh & Co Kg Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
CA2653105A1 (en) 2006-05-24 2007-11-29 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0614621D0 (en) * 2006-07-24 2006-08-30 3M Innovative Properties Co Metered dose dispensers
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
KR20090121338A (ko) * 2007-02-19 2009-11-25 씨아이피엘에이 엘티디. 두 개 이상의 기관지확장제 또는 기관지확장제와 코르티코스테로이드의 약제학적 조합
EP1964564A1 (en) * 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
EP2036572A1 (en) 2007-09-04 2009-03-18 Novo Nordisk A/S Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle
CN101317821B (zh) * 2007-11-15 2012-01-04 陈晓东 适用于肺部给药的超细干粉颗粒及其制备方法
PT2234595E (pt) * 2007-12-13 2013-01-24 Novartis Ag Processo para redução da tendência de um sal de glicopirrónio para se agregar durante a armazenagem
GB0801876D0 (en) 2008-02-01 2008-03-12 Vectura Group Plc Suspension formulations
FR2940162B1 (fr) 2008-12-22 2011-02-25 Boehm & Cie Ets Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension
WO2010097188A1 (en) * 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SMT202000077T1 (it) 2009-05-29 2020-03-13 Pearl Therapeutics Inc Composizioni per il rilascio polmonare di antagonisti muscarinici a lunga durata e agonisti dei recettori beta-2 adrenergici a lunga durata e metodi e sistemi associati
PL2552424T3 (pl) 2010-04-01 2018-10-31 Chiesi Farmaceutici S.P.A. Sposób wytwarzania cząstek nośnika do suchych proszków do inhalacji
EP2627317A4 (en) 2010-10-15 2014-08-20 Glaxo Group Ltd MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE
CA2827045A1 (en) 2011-02-17 2012-08-23 Cipla Limited Compositions of glycopyrrolate and a beta2-agonist
JO3510B1 (ar) 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
EA201490991A1 (ru) 2011-05-17 2014-09-30 Перл Терапьютикс, Инк. Композиции, способы и устройства для респираторной доставки двух или более активных средств
KR20160013134A (ko) 2013-05-22 2016-02-03 펄 테라퓨틱스 인코포레이티드 3 개 이상의 활성제의 호흡기 전달을 위한 조성물, 방법 및 시스템

Also Published As

Publication number Publication date
KR101748892B1 (ko) 2017-06-19
DK2435024T3 (en) 2016-10-24
ZA201208100B (en) 2013-07-31
PT3111926T (pt) 2020-02-28
US20150017247A1 (en) 2015-01-15
SI2435025T1 (sl) 2016-10-28
MX393243B (es) 2025-03-24
US10716753B2 (en) 2020-07-21
JP2012528200A (ja) 2012-11-12
HUE047823T2 (hu) 2020-05-28
AR076621A1 (es) 2011-06-22
SI2435024T1 (sl) 2016-10-28
TWI646980B (zh) 2019-01-11
JP6169639B2 (ja) 2017-07-26
US20180125776A1 (en) 2018-05-10
AR076807A1 (es) 2011-07-06
BRPI1011220B1 (pt) 2020-03-10
HK1244669A1 (zh) 2018-08-17
WO2010138862A2 (en) 2010-12-02
IL216468A0 (en) 2012-01-31
EP3106149A1 (en) 2016-12-21
MX350164B (es) 2017-08-29
ES2592536T3 (es) 2016-11-30
EP3111927B1 (en) 2019-12-11
EP2435025A2 (en) 2012-04-04
BRPI1011229B8 (pt) 2021-05-25
SI3111927T1 (sl) 2020-08-31
CA2763936A1 (en) 2010-12-02
EP3111927A1 (en) 2017-01-04
US20110132356A1 (en) 2011-06-09
WO2010138868A3 (en) 2011-04-28
CN107412212B (zh) 2021-01-22
DK3111926T3 (da) 2020-03-02
HRP20161101T1 (hr) 2016-11-04
CY1118030T1 (el) 2017-05-17
HUE031229T2 (en) 2017-06-28
TWI546094B (zh) 2016-08-21
ES2772253T3 (es) 2020-07-07
ES2774367T3 (es) 2020-07-20
HUE031283T2 (hu) 2017-07-28
WO2010138868A2 (en) 2010-12-02
CY1118034T1 (el) 2017-05-17
JP6189356B2 (ja) 2017-08-30
LTPA2021511I1 (enExample) 2021-06-25
TWI717511B (zh) 2021-02-01
JP2012528199A (ja) 2012-11-12
MX2011012684A (es) 2012-05-23
EP3111926B1 (en) 2019-12-11
RU2011152960A (ru) 2013-07-10
HK1247095A1 (zh) 2018-09-21
LTC2435024I2 (enExample) 2022-06-27
MX377778B (es) 2025-03-11
JP2018048150A (ja) 2018-03-29
EP2435023B1 (en) 2016-07-06
JP2012528792A (ja) 2012-11-15
SMT202000109T1 (it) 2020-03-13
PT3106149T (pt) 2020-02-19
PH12017500778A1 (en) 2018-01-22
CA2763941A1 (en) 2010-12-02
MX2011012783A (es) 2012-06-28
CY2019031I1 (el) 2019-11-27
SI3111926T1 (sl) 2020-07-31
HUE029532T2 (en) 2017-03-28
PL2435023T3 (pl) 2017-06-30
LT2435024T (lt) 2016-09-26
RU2751771C2 (ru) 2021-07-16
HRP20200166T1 (hr) 2020-05-15
LT2435023T (lt) 2016-09-26
AU2010253950A1 (en) 2011-12-08
PL2435025T3 (pl) 2017-08-31
MX337126B (es) 2016-02-12
TW201700123A (zh) 2017-01-01
PL3106149T3 (pl) 2020-06-01
PL2435024T3 (pl) 2017-01-31
PT2435024T (pt) 2016-10-13
KR20120034631A (ko) 2012-04-12
LTC2435025I2 (lt) 2021-02-10
HRP20161098T1 (hr) 2016-10-21
NO2019026I1 (no) 2019-06-13
LT3111926T (lt) 2020-03-25
RU2020102859A (ru) 2021-07-26
RU2580315C3 (ru) 2021-06-18
ES2589135T3 (es) 2016-11-10
CY2021012I1 (el) 2021-10-15
IL216467A0 (en) 2012-01-31
EP3111926A1 (en) 2017-01-04
HRP20200260T1 (hr) 2020-05-29
CA2763939A1 (en) 2010-12-02
LUC00208I2 (enExample) 2022-10-07
US20110132357A1 (en) 2011-06-09
CY1122732T1 (el) 2021-03-12
RU2016107464A (ru) 2018-11-22
AU2010253950B2 (en) 2014-12-04
TW202114642A (zh) 2021-04-16
KR20120026075A (ko) 2012-03-16
JP6348645B2 (ja) 2018-06-27
EP2435024B1 (en) 2016-07-06
TW201109049A (en) 2011-03-16
RU2016117972A (ru) 2018-10-29
CN105193773B (zh) 2018-12-11
TW201109051A (en) 2011-03-16
AU2010253770A1 (en) 2011-11-24
KR101976107B1 (ko) 2019-05-09
SI2435023T1 (sl) 2016-10-28
TW201808372A (zh) 2018-03-16
HUS2100018I1 (hu) 2021-06-28
NO2021019I1 (no) 2021-05-12
JP2015187108A (ja) 2015-10-29
LT3106149T (lt) 2020-03-10
US9463161B2 (en) 2016-10-11
US8808713B2 (en) 2014-08-19
KR101926060B1 (ko) 2018-12-06
TWI695723B (zh) 2020-06-11
AR076806A1 (es) 2011-07-06
CN102458364A (zh) 2012-05-16
CN102596176B (zh) 2017-09-19
CN107412212A (zh) 2017-12-01
JP2015199735A (ja) 2015-11-12
JP2016041713A (ja) 2016-03-31
NL300995I1 (enExample) 2019-06-24
JP2019108369A (ja) 2019-07-04
RU2011154083A (ru) 2013-07-10
ES2774391T3 (es) 2020-07-20
CY1122749T1 (el) 2021-03-12
LUC00124I1 (enExample) 2019-06-13
NL300995I2 (nl) 2019-10-29
SMT201600326B (it) 2016-11-10
FR19C1040I2 (fr) 2020-07-31
JP2018008942A (ja) 2018-01-18
KR20170104003A (ko) 2017-09-13
PT3111927T (pt) 2020-03-03
PL3111927T3 (pl) 2020-06-29
PT2435023T (pt) 2016-10-14
RU2015151358A (ru) 2019-01-16
MX2020004077A (es) 2020-07-29
ZA201208101B (en) 2013-07-31
LTPA2019014I1 (lt) 2019-07-10
HRP20161102T1 (hr) 2016-11-04
MX350163B (es) 2017-08-29
JP6876734B2 (ja) 2021-05-26
EP2435024A2 (en) 2012-04-04
TW201936174A (zh) 2019-09-16
SI3106149T1 (sl) 2020-07-31
RU2580315C2 (ru) 2016-04-10
HK1218867A1 (zh) 2017-03-17
ES2593429T3 (es) 2016-12-09
HUS1900031I1 (hu) 2019-07-29
HUE047803T2 (hu) 2020-05-28
DK2435023T3 (en) 2016-10-24
HK1169027A1 (zh) 2013-01-18
IL216466A0 (en) 2012-01-31
KR20120015334A (ko) 2012-02-21
DK2435025T3 (en) 2016-10-24
EP3106149B1 (en) 2019-11-20
ZA201208102B (en) 2013-09-25
CN102458364B (zh) 2016-11-02
RU2015151358A3 (enExample) 2019-07-29
SMT201600327B (it) 2016-11-10
WO2010138884A3 (en) 2011-04-21
RU2713404C2 (ru) 2020-02-05
TWI539979B (zh) 2016-07-01
AU2010253776B2 (en) 2015-01-22
WO2010138884A2 (en) 2010-12-02
US20250009652A1 (en) 2025-01-09
HK1169307A1 (zh) 2013-01-25
AU2010253770B9 (en) 2015-02-12
US20170071850A1 (en) 2017-03-16
ME03631B (me) 2020-07-20
PT2435025T (pt) 2016-11-11
SMT202000108T1 (it) 2020-03-13
KR20170070274A (ko) 2017-06-21
PL3111926T3 (pl) 2020-06-29
KR20190049943A (ko) 2019-05-09
RU2016107464A3 (enExample) 2019-08-19
LUC00124I2 (enExample) 2019-12-27
CN102596176A (zh) 2012-07-18
LT2435025T (lt) 2016-09-26
AU2010253770B2 (en) 2014-12-11
CN105193773A (zh) 2015-12-30
CY1118040T1 (el) 2017-05-17
RU2016117972A3 (enExample) 2019-09-27
SMT202000077T1 (it) 2020-03-13
US20170112759A1 (en) 2017-04-27
CY2019031I2 (el) 2019-11-27
AU2010253950C1 (en) 2015-09-17
MX2011012685A (es) 2012-06-12
EP2435023A2 (en) 2012-04-04
IL216467B (en) 2018-12-31
DK3106149T3 (da) 2020-02-24
CY2021012I2 (el) 2021-10-15
FR19C1040I1 (enExample) 2020-07-31
US20190307676A1 (en) 2019-10-10
CN102753152A (zh) 2012-10-24
JP6492124B2 (ja) 2019-03-27
BRPI1011220A2 (pt) 2016-03-15
US20190038548A1 (en) 2019-02-07
HK1169026A1 (zh) 2013-01-18
KR20180130602A (ko) 2018-12-07
RU2586297C2 (ru) 2016-06-10
TW201109050A (en) 2011-03-16
TWI707700B (zh) 2020-10-21
JP2017222706A (ja) 2017-12-21
HRP20200298T1 (hr) 2020-06-12
US20210186861A1 (en) 2021-06-24
CN102753152B (zh) 2015-09-23
TWI792140B (zh) 2023-02-11
CA2763936C (en) 2017-10-03
CY1122807T1 (el) 2021-05-05
TW201642836A (zh) 2016-12-16
CN107669664A (zh) 2018-02-09
TWI632926B (zh) 2018-08-21
IL216468B (en) 2018-12-31
JP5823383B2 (ja) 2015-11-25
HUE047834T2 (hu) 2020-05-28
RU2011154148A (ru) 2013-07-10
TWI633898B (zh) 2018-09-01
WO2010138862A3 (en) 2011-04-14
ZA201108275B (en) 2023-04-26
BRPI1011229B1 (pt) 2020-10-13
JP5873013B2 (ja) 2016-03-01
BRPI1011229A2 (pt) 2016-03-15
EP2435025B1 (en) 2016-07-06
CN107669664B (zh) 2020-07-10
BRPI1011508A2 (pt) 2016-03-22
JP5873012B2 (ja) 2016-03-01
US20110023876A1 (en) 2011-02-03
US20110135737A1 (en) 2011-06-09
DK3111927T3 (da) 2020-03-09
TW201919730A (zh) 2019-06-01
SMT201600329B (it) 2016-11-10
LT3111927T (lt) 2020-03-25
AU2010253776A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
IL216466B (en) Compositions for respiratory delivery of active agents and associated methods and systems
IL262376A (en) Method and system for drug delivery
IL232258A0 (en) Dermal delivery compositions and methods
IL221412A0 (en) System and method for administering medicaments on the basis of urine values
IL250259A0 (en) Compositions comprising ursolic acid and derivatives thereof and uses thereof
IL229400A0 (en) Controlled release nasal testosterone gels,methods and pre-filled multi-dose applicator systems for pernasal administration
BR112013002445A2 (pt) shampoo anticaspa e uso de um sistema de surfactante
EP2531249A4 (en) NITROGEN OXIDE OUTPUT SYSTEM
EP2683328A4 (en) RELEASE SYSTEM
EP2863892A4 (en) MUKOADHESIVE NANOPARTICLE RELIEF SYSTEM
IL225829A0 (en) Apparatus, methods, and compositions for endodontic treatments
BRPI1010234A2 (pt) "fornecimento de armazenagem de estado em processador para modo de administração de sistemas"
HRP20180497T1 (hr) Antimikrobni pripravci i odgovarajući postupci njihove upotrebe
FI20105860A0 (fi) Aktiivinen paikannusjärjestelmä
FI20130087L (fi) Patjan rakenne, patjajärjestelmä ja patjan käyttötapa
BR112013009965A2 (pt) "sistema e método"
IL232325A0 (en) 18-methyl-7,6-methylene-3-oxo-17-paragan-4-en-21, 17b-carbolactones, pharmaceutical preparations containing these compounds and their use for the treatment of endometrial disease
HUE052137T2 (hu) Transzdermális gyógyászati rendszer egy hatóanyag adagolására
PL2729008T3 (pl) Systemy, sposoby i formulacje do leczenia raka
SMT201600190B (it) Uso di streptococcus salivarius nel trattamento di infezioni croniche dell'apparato respiratorio
IT1401531B1 (it) Sistema utilizzabile in due modalita'
IL226003A (en) Terence of trans - 2 - Decanoic acid and its pharmacist
CR20130174A (es) Sistema y composiciones mejorados para la administración transbucal de fármacos
EP2542564A4 (en) SYSTEM FOR TAXED RELEASE
FR2941371B1 (fr) Dispositif de preparation extemporanee de preparations medicamenteuses

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed